Yopp Adam C, Mansour John C, Beg Muhammad S, Arenas Juan, Trimmer Clayton, Reddick Mark, Pedrosa Ivan, Khatri Gaurav, Yakoo Takeshi, Meyer Jeffrey J, Shaw Jacqueline, Marrero Jorge A, Singal Amit G
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA,
Ann Surg Oncol. 2014 Apr;21(4):1287-95. doi: 10.1245/s10434-013-3413-8. Epub 2013 Dec 7.
To evaluate differences in overall survival in patients with hepatocellular carcinoma (HCC) after the establishment of a multidisciplinary clinic (MDC) for HCC.
Patient demographic and tumor characteristics of 355 patients diagnosed with HCC were collected between October 2006 and September 2011. Patients diagnosed after the initiation of the HCC MDC on October 1, 2010, were compared to patients diagnosed in the 4 years before. Patient demographics, tumor characteristics, treatment regimens, and overall survival were analyzed between the groups.
A total of 105 patients were diagnosed in the time period after HCC MDC initiation compared to 250 patients in the previous 4 years. Patients diagnosed with HCC after the HCC MDC had fewer symptoms at presentation (64 vs. 78 %, p = 0.01) and earlier stage of tumor presentation [Barcelona Clinic for Liver Cancer (BCLC) A stage, 44 vs. 26 %, p = 0.0003; tumor, node, metastasis classification system stage 1, 44 vs. 30 %, p = 0.003) compared with patients diagnosed before MDC formation. The median time to treatment after diagnosis in the later period was significantly shorter than in the earlier time period (2.3 vs. 5.3 months, p = 0.002). On multivariate analysis, being seen in the HCC MDC remained independently associated with better overall survival (hazard ratio 2.5, 95 % confidence interval 2-3), after adjusting for BCLC stage and recipient of curative treatment. Patients diagnosed after HCC MDC initiation had a median survival of 13.2 months compared to the 4.8 months observed in patients diagnosed before MDC formation (p = 0.005).
The implementation of a MDC for the evaluation and treatment of patients with HCC is associated with improved overall survival.
评估多学科肝癌诊疗门诊(MDC)设立后肝细胞癌(HCC)患者总生存期的差异。
收集2006年10月至2011年9月期间确诊为HCC的355例患者的人口统计学资料和肿瘤特征。将2010年10月1日HCC MDC启动后确诊的患者与之前4年确诊的患者进行比较。分析两组患者的人口统计学资料、肿瘤特征、治疗方案和总生存期。
HCC MDC启动后的时间段内共确诊105例患者,而前4年为250例。HCC MDC启动后确诊的HCC患者就诊时症状较少(64%对78%,p = 0.01),肿瘤就诊分期较早[巴塞罗那肝癌临床(BCLC)A期,44%对26%,p = 0.0003;肿瘤-淋巴结-转移分类系统1期,44%对30%,p = 0.003],与MDC形成前确诊的患者相比。后期诊断后至治疗的中位时间明显短于早期(2.3个月对5.3个月,p = 0.002)。多因素分析显示,在调整BCLC分期和接受根治性治疗情况后,在HCC MDC就诊仍与更好的总生存期独立相关(风险比2.5,95%置信区间2 - 3)。HCC MDC启动后确诊的患者中位生存期为13.2个月,而MDC形成前确诊的患者为4.8个月(p = 0.005)。
实施MDC用于评估和治疗HCC患者与总生存期改善相关。